Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan,Matthew J Maurer,Wendy Stock,Nancy L Bartlett,Noreen Fulton,Adam Pettinger,John C Byrd,Kristie A Blum,Ann S Lacasce,David Duane Hurd,Amy S Ruppert,Francisco J Hernandez-Ilizaliturri,John P Leonard,Bruce Cheson

doi:10.1182/blood-2018-99-112655

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan, Matthew J Maurer + Show 12 more

Open Access

https://doi.org/10.1182/blood-2018-99-112655

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 6

Affiliation: University of California, San Francisco, Mayo Clinic, University of Chicago, Washington University in St. Louis, The Ohio State University, The Ohio State University Wexner Medical Center, Dana-Farber Cancer Institute, Wake Forest University, Roswell Park Cancer Institute, Cornell University, Georgetown University

#Bortezomib Maintenance #Bortezomib Consolidation + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.